Peritoneal dialysis composition
By adding sodium pyruvate and betaine to the peritoneal dialysate, the problems of peritoneal fibrosis and ultrafiltration failure caused by high concentration of glucose were solved, which significantly extended the service life of peritoneal dialysis and improved the ultrafiltration effect.
Patent Information
- Application Number
- CN202410928447.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-06
- Publication Date
- 2024-11-08
AI Technical Summary
In the existing peritoneal dialysis technology, high concentration of glucose solutions leads to peritoneal fibrosis and ultrafiltration failure, and the existing alternative solutions fail to effectively prevent peritoneal cell death and fibrosis.
Peritoneal dialysis compositions including sodium pyruvate and betaine are used to reduce peritoneal cell mortality and improve ultrafiltration effects by mixing them with existing peritoneal dialysate.
It significantly delays the occurrence time of ultrafiltration failure of peritoneal dialysis, protects peritoneal cells, improves the ultrafiltration effect of peritoneal dialysis, and reduces peritoneal fibrosis.
Smart Images

Figure CN118903082A_ABST
Abstract
Description
[0001] This application is a divisional application of application number 2022106298894, filing date June 6, 2022, and invention name "A peritoneal dialysis composition." Technical Field
[0002] The invention belongs to the field of biotechnology, and in particular relates to a peritoneal dialysis composition. Background Art
[0003] Peritoneal dialysis (PD) is one of the main renal replacement therapies for patients with uremic end-stage renal disease (ESRD). In PD, a hypertonic solution is used to remove excess water from the body through the peritoneum (PM). Currently, the most commonly used osmotic agent in PD solution is a glucose solution with a concentration of 1.5% to 4.25%, such as Dianeal from Baxter (Deerfield, IL, USA). As the dialysis time increases, low-concentration glucose dialysate will soon be unable to draw out enough water, and high-concentration glucose dialysate must be used as the dialysate. As the number of times high-concentration glucose dialysate is used increases, the dialysis efficiency usually decreases after 2 years of dialysis, making it impossible for patients to continue to rely solely on peritoneal dialysis and must switch to hemodialysis. According to statistics, the incidence of ultrafiltration failure increases with the extension of PD years, and ultrafiltration failure is the main reason why peritoneal dialysis patients are forced to withdraw from peritoneal dialysis. Preventing and slowing down peritoneal fibrosis is the fundamental way to avoid ultrafiltration failure in peritoneal dialysis patients and is the key to ensuring their long-term dialysis success and prolonging their lifespan.
[0004] Peritoneal tissue consists of three layers: the mesothelial layer, the basal layer, and the submesothelial support tissue. The submesothelial support tissue is rich in microvessels, and mesothelial cells and submesothelial microvessels are the most important cellular and structural basis for peritoneal dialysis. Morphologically, peritoneal fibrosis is manifested as a decrease in mesothelial cells, the replacement of dead mesothelial cells by myofibroblasts or fibroblasts, the infiltration of inflammatory cells, and the accumulation of a large number of extracellular matrix accompanied by an increase in the number of blood vessels. Therefore, the death of mesothelial cells and peritoneal inflammation are the root causes of peritoneal fibrosis. The current mainstream view is that the factors that lead to mesothelial cell death and peritoneal inflammation are high-concentration glucose itself, as well as abnormal cell metabolism induced by high-concentration glucose and the free radicals produced. Therefore, in recent years, more scientific research and clinical studies have been devoted to seeking dialysates that replace high-concentration glucose solutions, but unfortunately, they have failed to achieve the effect of preventing peritoneal fibrosis.
[0005] In the invention patent CN109394781 A, glucose polymer is used instead of glucose. The molecular volume of glucose polymer is large and it cannot directly diffuse through the peritoneal wall into the peritoneal microvessels and be absorbed by the body. Therefore, a high colloid osmotic pressure is generated in the peritoneal cavity to maintain the dehydration and clearance efficiency during the retention period, reduce the occurrence of inflammation related to the dialysis process, and prolong the dialysis life of peritoneal dialysis patients. Icodextrin dialysis fluid with polydextrose as the osmotic fluid is one of them. In the article "Icodextrin and peritoneal dialysis: advantages and new applications" ("Int Urol Nephrol" 2018 Issue 3) published by Dousdampanis et al., icodextrin is used instead of traditional high-concentration glucose as peritoneal dialysis fluid. Icodextrin is a water-soluble glucose polymer connected by α(1-4) and α(1-6) glycosidic bonds, with an average relative molecular mass of 16200Da. Currently, the dialysis fluid containing 7.5% icodextrin produced by Baxter is available on the market, with an osmotic pressure of 285mosm / L, which is equal to the osmotic pressure of the human body, and mainly utilizes the colloid osmotic pressure to isotonically remove water through the small holes on the peritoneum.
[0006] Whether it is peritoneal dialysis fluid containing glucose or polysaccharide icodextrin peritoneal dialysis fluid, both are ultrafiltration dehydration through crystal or colloid osmotic pressure. High osmotic pressure may cause osmotic damage or death of peritoneal mesothelial cells. Therefore, the key problem that peritoneal dialysis technology needs to solve at present is how to protect peritoneal cells, especially peritoneal mesothelial cells, on the basis of glucose or other dialysates used clinically, so as to prevent peritoneal fibrosis and ultrafiltration failure. Summary of the invention
[0007] The object of the present invention is to provide a peritoneal dialysis composition which can protect peritoneal cells and further reduce the mortality rate of peritoneal cells.
[0008] In order to solve the above technical problems, the present invention adopts the following technical solutions:
[0009] A peritoneal dialysis composition comprises a peritoneal dialysis solution, and the peritoneal dialysis composition further comprises sodium pyruvate and betaine.
[0010] Betaine as an osmotic regulator combined with sodium pyruvate can further reduce peritoneal cell mortality.
[0011] Preferably, the concentration of sodium pyruvate in the peritoneal dialysis composition is 1-300 mg / L.
[0012] More preferably, the concentration of sodium pyruvate in the peritoneal dialysis composition is 50-150 mg / L.
[0013] Preferably, the concentration of betaine in the peritoneal dialysis composition is 0.01-1000 mmol / L.
[0014] More preferably, the concentration of betaine in the peritoneal dialysis composition is 1-500 mmol / L.
[0015] The peritoneal dialysis fluid described in the present invention is an existing disclosed and commercialized peritoneal dialysis fluid, a peritoneal dialysis fluid routinely used in clinical practice, or a peritoneal dialysis fluid that can be used in clinical practice in theory.
[0016] Preferably, the peritoneal dialysis fluid is one or more of glucose peritoneal dialysis fluid, amino acid peritoneal dialysis fluid, dextran peritoneal dialysis fluid or icodextrin peritoneal dialysis fluid.
[0017] According to some embodiments, the peritoneal dialysis fluid is 1.5% to 4.25% glucose peritoneal dialysis fluid, 1.5% to 4.25% amino acid peritoneal dialysis fluid, 1.5% to 4.25% dextran peritoneal dialysis fluid or 6% to 8% icodextrin peritoneal dialysis fluid.
[0018] According to some embodiments, each 100 mL of peritoneal dialysis fluid includes the following components:
[0019]
[0020] The pH value of the peritoneal dialysis fluid is 4.5 to 6.5.
[0021] The peritoneal dialysis fluid matrix is one or more of glucose, amino acids or dextran. According to other embodiments, each 100 mL of peritoneal dialysis fluid includes the following components:
[0022] The pH value of the peritoneal dialysis fluid is 5.0-6.0.
[0023] For example, each 100 mL of peritoneal dialysis fluid contains the following components:
[0024]
[0025] The pH value of the peritoneal dialysis fluid is 4.5 to 6.0;
[0026] or,
[0027] Each 100 mL of peritoneal dialysis fluid contains the following ingredients:
[0028]
[0029] The pH value of the peritoneal dialysis fluid is 4.5 to 6.5;
[0030] or,
[0031] Each 100 mL of peritoneal dialysis fluid contains the following ingredients:
[0032]
[0033]
[0034] The pH value of the peritoneal dialysis fluid is 4.5 to 6.5;
[0035] or,
[0036] Each 100 mL of peritoneal dialysis fluid contains the following ingredients:
[0037]
[0038] The pH value of the peritoneal dialysis fluid is 5.0-6.0.
[0039] The above-mentioned specific peritoneal dialysis fluids are for illustration only and do not limit betaine and sodium pyruvate to be used only in these peritoneal dialysis fluids. In theory, any available peritoneal dialysis fluid combined with betaine and sodium pyruvate can effectively reduce cell pyroptosis and improve the ultrafiltration effect of peritoneal dialysis.
[0040] The present invention also provides a method for preparing the peritoneal dialysis composition, wherein the preparation method comprises directly mixing the sodium pyruvate and betaine with the peritoneal dialysis solution, or mixing the sodium pyruvate and betaine with the raw materials of the peritoneal dialysis solution to obtain the peritoneal dialysis composition.
[0041] Compared with the prior art, the present invention has the following advantages:
[0042] The present invention combines sodium pyruvate with osmotic regulating substances such as betaine for the first time, and finds that the cell protection effect of peritoneal dialysis fluid can be further improved. Without adjusting the formula of commercial or clinically commonly used peritoneal dialysis fluid, directly adding a small amount of sodium pyruvate and betaine to the existing peritoneal fluid can effectively reduce cell pyroptosis, improve the ultrafiltration effect of peritoneal dialysis, and significantly delay the occurrence time of peritoneal dialysis ultrafiltration failure. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 Light microscopic images of cells treated with 4.25% glucose for 24 hours while being given different concentrations of betaine;
[0044] Figure 2 The crystal violet staining images of cells treated with 4.25% glucose for 24 hours while giving different concentrations of betaine;
[0045] Figure 3The results of the detection and analysis of the cell LDH release rate when different concentrations of betaine were given to the cells and treated with 4.25% glucose for 24 hours;
[0046] Figure 4 The electrophoresis diagram of Caspase 3 protein, GSDME protein and β-Actin expression in cells treated with 4.25% glucose for 24 hours with different concentrations of betaine.
[0047] Figure 5 Light microscopic images of cells treated with different concentrations of sodium pyruvate and 4.25% glucose for 24 hours;
[0048] Figure 6 Crystal violet staining photos of cells treated with different concentrations of sodium pyruvate and 4.25% glucose for 24 hours;
[0049] Figure 7 The results of the detection and analysis of the cell LDH release rate when different concentrations of sodium pyruvate were given to the cells at the same time as 4.25% glucose for 24 hours;
[0050] Figure 8 The electrophoresis diagram of Caspase 3 protein, GSDME protein and β-Actin expression in cells treated with different concentrations of sodium pyruvate and 4.25% glucose for 24 hours was detected by Western blot;
[0051] Fig. 9 Light microscopic images of cells treated with 4.25% glucose for 24 hours after betaine and sodium pyruvate were given to the cells simultaneously;
[0052] Fig.10 This is a crystal violet staining image of cells treated with 4.25% glucose for 24 hours after betaine and sodium pyruvate were given to the cells simultaneously;
[0053] Fig.11 This is a graph showing the results of the detection and analysis of the cell LDH release rate when betaine and sodium pyruvate were simultaneously administered to cells treated with 4.25% glucose for 24 hours;
[0054] Fig.12 The electrophoresis diagram of caspase 3 protein, GSDME protein and β-Actin expression in cells treated with 4.25% glucose for 24 hours by Western blot;
[0055] Fig.13 This is the measurement result of the mouse peritoneal dialysis ultrafiltration volume UF;
[0056] Fig.14This is the detection and analysis diagram of LDH content in dialysate after peritoneal dialysis in mice;
[0057] Fig.15 The figure shows the Masson staining result of peritoneal tissue after peritoneal dialysis of mice (Scale bar = 100 μm). DETAILED DESCRIPTION
[0058] The present invention is further described below in conjunction with the examples. However, the present invention is not limited to the following examples. The implementation conditions used in the examples can be further adjusted according to the different requirements of specific use, and the implementation conditions not specified are conventional conditions in the industry. The technical features involved in each embodiment of the present invention can be combined with each other as long as they do not conflict with each other.
[0059] In previous studies, the inventors found that the differences in the dialysate matrix of commercial or clinically commonly used peritoneal fluids, such as glucose peritoneal dialysis fluid, amino acid peritoneal dialysis fluid, dextran peritoneal dialysis fluid or icodextrin peritoneal dialysis fluid, have little effect on cell survival. However, if betaine, a crystal or colloidal osmotic regulating substance normally produced in the body or exogenous, is added to the above peritoneal dialysis fluid, it can provide hyperosmotic protection for peritoneal mesothelial cells to help the cells self-regulate the hyperosmotic environment, so that peritoneal mesothelial cells can better adapt to the hyperosmotic environment, reduce cell death such as cell pyroptosis and apoptosis, thereby reducing peritoneal fibrosis and significantly delaying the occurrence of peritoneal dialysis ultrafiltration failure.
[0060] As the research progressed, the inventor accidentally discovered after extensive research that when betaine is used in combination with sodium pyruvate, it can further enhance the hyperosmotic protective effect on peritoneal mesothelial cells, and the cell death rate in the hyperosmotic glucose dialysate is further reduced. Therefore, an optimized peritoneal dialysis fluid was developed. Without the need to adjust the formula of the existing commercial or clinically used peritoneal dialysis fluid, a small amount of sodium pyruvate and the osmotic protective substance betaine are directly added to the existing peritoneal dialysis fluid, which can effectively reduce cell death such as cell pyroptosis and cell apoptosis, and significantly delay the occurrence of peritoneal dialysis ultrafiltration failure.
[0061] More specifically, the concentration of sodium pyruvate in the peritoneal dialysis composition is 1-250 mg / L, for example, 10 mg / L, 20 mg / L, 50 mg / L, 60 mg / L, 70 mg / L, 80 mg / L, 90 mg / L, 100 mg / L, 110 mg / L, 120 mg / L, 130 mg / L, 140 mg / L, 150 mg / L, 160 mg / L, 170 mg / L, 180 mg / L, 190 mg / L, 200 mg / L, 210 mg / L, 220 mg / L, 230 mg / L, 240 mg / L, 250 mg / L.
[0062] More specifically, the concentration of betaine in the peritoneal dialysis solution is 0.01 to 1000mmol / L, for example, 0.01mmol / L, 0.05mmol / L, 1mmol / L, 50mmol / L, 100mmol / L, 150mmol / L, 200mmol / L, 250mmol / L, 300mmol / L, 350mmol / L, 400mmol / L, 450mmol / L, 500mmol / L, 550mmol / L, 600mmol / L, 650mmol / L, 700mmol / L, 750mmol / L, 800mmol / L, 850mmol / L, 900mmol / L, 950mmol / L, and 1000mmol / L.
[0063] The technical scheme and technical effects of the present invention are explained below in conjunction with specific experiments.
[0064] The 4.25% glucose hypertonic peritoneal dialysis solution (Baxter, 6AB9796) in the following example has the following formula: 4.25 g glucose, 538 mg sodium chloride, 18.3 mg calcium chloride, 5.1 mg magnesium chloride, 448 mg lactate, and a pH value of about 5.2 per 100 mL peritoneal dialysis solution.
[0065] Example 1: Betaine can alleviate hyperosmotic-induced pyroptosis of peritoneal mesothelial cells
[0066] Human peritoneal mesothelial cell line HMrSV5: The culture medium is DMEM high-glucose medium (hyclone, Cat No: SH30022.01) containing 10% (v / v) FBS and 1% penicillin / streptomycin, and the cells are cultured in a 37°C, 5% CO2 incubator. The cell growth state is observed and the culture medium is replaced every 2 days. The cells are passaged after reaching 90% confluence, and the cells are digested with 0.25% trypsin at 37 degrees for 3 minutes. After terminating the digestion, the cells are collected, 1000r, room temperature, 5 minutes, centrifuged, resuspended with complete culture medium and counted, plated, six-well plate, 700,000 / well. Mesothelial cells were attached to the wall for 16-24 hours and then starved for 12 hours. Different concentrations of betaine (0.5mM, 5mM, 7mM, 10mM) were given to the cells and high glucose (Glu 236mM) was treated for 24 hours. It was observed that the cells grew well after being treated with different betaine alone. When treated with 236mM glucose at the same time, it was found that cell survival was significantly improved starting from 1mM betaine, and cell death gradually decreased with increasing doses ( Figure 1 ); Crystal violet staining results showed that the cell survival rate increased in a dose-dependent manner after betaine treatment ( Figure 2 ); The amount of lactate dehydrogenase (LDH) released from cells into the supernatant decreased with the increase of betaine dose ( Figure 3 ), the cleavage and activation of apoptosis and pyroptosis molecules Caspase-3 were reduced, and the cleavage and activation of pyroptosis molecules GSDME were significantly inhibited ( Figure 4 ). Figure 1 to Figure 4 The results demonstrated that betaine may play a protective role in the response of peritoneal mesothelial cells to high glucose and hyperosmotic environment.
[0067] Embodiment 2:
[0068] The experimental steps are the same as those in Example 1, except that betaine is replaced with sodium pyruvate.
[0069] Peritoneal mesothelial cells were given different concentrations of sodium pyruvate (50mg / L, 70mg / L, 100mg / L, 150mg / L) and high glucose (Glu 236mM) for 24 hours. Optical microscopy showed that when cells were pretreated with different concentrations of sodium pyruvate and then treated with 236mM glucose, cell survival was significantly improved starting from 50mg / L sodium pyruvate, and cell death gradually decreased with increasing doses ( Figure 1 ); Crystal violet staining results showed that the cell survival rate increased in a dose-dependent manner after sodium pyruvate treatment ( Figure 2 ); LDH released into the supernatant by cells decreased with increasing doses of sodium pyruvate ( Figure 3 ), the cleavage and activation of Caspase 3 protein was significantly reduced, and the cleavage and activation of GSDME, a marker protein of cell pyroptosis, was also significantly reduced, which proved that sodium pyruvate plays a protective role in peritoneal mesothelial cells against high glucose and hyperosmotic environment.
[0070] Embodiment three:
[0071] Peritoneal mesothelial cells were treated with different concentrations of betaine (5mM, 7mM) and high glucose (Glu 236mM) for 24 hours, different concentrations of sodium pyruvate (70mg / L, 150mg / L) and high glucose (Glu 236mM) for 24 hours, and betaine, sodium pyruvate and high glucose (Glu 236mM) for 24 hours (same steps as in Example 1). Optical microscopy observation showed that when 4.25% glucose was pretreated with sodium pyruvate and betaine at the same time, the survival of cells pretreated with betaine and sodium pyruvate was significantly improved compared with cells pretreated with sodium pyruvate and betaine alone, and cell death gradually decreased with increasing doses ( Fig. 9 ), crystal violet staining results showed that the cell survival rate increased in a dose-dependent manner after betaine treatment ( Fig.10 ), the LDH released into the supernatant by cells decreased with increasing betaine dose ( Fig.11), the cleavage of Caspase 3 protein was significantly reduced, and the cleavage activation of GSDME, a marker protein of cell pyroptosis, was also significantly reduced ( Fig.12 ), which proves that the simultaneous administration of appropriate doses of sodium pyruvate and betaine to cells can play a stronger protective role in the peritoneal mesothelial cells against the high glucose and hyperosmotic environment.
[0072] Embodiment 4:
[0073] The mouse peritoneal fibrosis model was established by intraperitoneal injection of hypertonic peritoneal dialysis fluid (4.25% PD) into the mouse peritoneal cavity. 16 C57WT mice were divided into three groups. The control group n=4: daily intraperitoneal injection of 0.9% NS at 120ml / kg body weight + sterile saline with the same volume of therapeutic dose of betaine. The model group n=6: daily intraperitoneal injection of 4.25% peritoneal dialysis fluid at 120ml / kg body weight + 4.25% peritoneal dialysis fluid with the same volume of betaine. Betaine treatment group (n=6): daily intraperitoneal injection of 4.25% peritoneal dialysis fluid at 120ml / kg body weight + betaine 10mM (betaine was mixed with peritoneal dialysis fluid, and the final concentration of betaine in the mixture was 10mM), for a total of 6 weeks. The betaine treatment group was treated at the same time as the simple model group. There was no significant difference in the body weight of mice in each group at the beginning of the experiment. From the first day, the body weight of mice was monitored and recorded every day. Finally, two mice withdrew from the experiment, one in the model group and one in the betaine treatment group. Both had a significant weight loss for unknown reasons, and turbid ascites was found after the abdominal cavity was opened at 6 weeks. The rest of the mice had normal eating and activity, good mental state, and increased weight compared to the beginning. After the end of the experiment, the weight statistics showed that the weight of the model group was lower than that of the normal control group, while the weight of the betaine treatment group was slightly higher than that of the model group, but still lower than that of the normal control group. However, there was no significant statistical difference in statistical analysis.
[0074] Animal sample collection, specimen processing and preservation
[0075] In the sixth week of the experiment, a peritoneal balance test was performed to monitor peritoneal function and to obtain tissue samples from mice. After the mice stopped peritoneal dialysis for 48 hours, a 2-hour peritoneal balance test was performed. The mice were anesthetized by intramuscular injection of 1% sodium pentobarbital at 0.07 ml / 10 g.
[0076] After the mouse is anesthetized, it is fixed on the operating table in a supine position, the abdomen is routinely disinfected, and a sterile surgical drape is laid. The operator wears a sterile surgical gown, a mask and sterile gloves. Then, a small cut of the skin is made along the linea alba with sterilized tweezers. Each mouse is intraperitoneally injected with 3 mL of 4.25% peritoneal dialysis fluid, and the timer is used for timing. The abdomen needs to be gently shaken during the dialysis process. After retaining in the abdominal cavity for 1 hour, 100 ul of dialysis fluid is withdrawn into a clean 600 ul EP tube and placed on ice. Then 100 ul of blood is collected from the tail vein in the EP tube and marked. After retaining in the abdominal cavity for 2 hours, the dialysis fluid in the abdominal cavity is withdrawn with a sterile syringe until it is exhausted. The volume of peritoneal dialysis fluid in the syringe is read and placed in a 5 ml centrifuge tube and marked. At the same time, 100 ul of blood is collected from the tail vein. Then use a scalpel to open the abdominal cavity along the linea alba, and bluntly separate the fascia and muscles layer by layer to avoid damaging small blood vessels or wiping the blood that oozes out after the rupture of small blood vessels, so as to prevent blood from flowing into the abdominal cavity and affecting the calculation of the ultrafiltration value of the peritoneal dialysis fluid. Ultrafiltration volume: Gently dip the sterile gauze into the fluid in the abdominal cavity, and calculate the net increase in the volume of the gauze. Ultrafiltration volume (UF) = the volume of the dialysate in the syringe + the net increase in the volume of the gauze - 3ml.
[0077] Sampling: Fully expose the abdominal wall, take the parietal peritoneum on both sides of the abdominal incision, wash it several times in pre-cooled PBS, cut it into small pieces, fix it in 4% PFA (the volume of PFA is more than 10 times the volume of the tissue), embed it in OCT and quickly put it into liquid nitrogen, and put it into 1.5ml EP tube into liquid nitrogen for protein and RNA detection. Observe the appearance of the mesentery and other visceral peritoneum, take part of the visceral peritoneum and put it into EP tubes, mark it, and immediately freeze it in liquid nitrogen, and then freeze the samples in liquid nitrogen at -80℃ as soon as possible. The tubes containing tissues and 4% PFA are stored at 4 degrees.
[0078] Separation of peritoneal dialysis fluid: Place the 600ul centrifuge tube containing peritoneal dialysis fluid samples after 1h and 2h of peritoneal retention in a 4-degree centrifuge at 3500r, 4 degrees, 10 minutes. After centrifugation, carefully transfer the supernatant to a new 600ul EP tube and immediately perform index detection or temporarily store at -20 degrees.
[0079] Isolate cells from peritoneal dialysis fluid: Place the recovered peritoneal dialysis fluid on ice, centrifuge at 3500rpm, 4 degrees, for 10 minutes, transfer the peritoneal dialysis fluid supernatant, and break the red blood cells if there are red blood cells in the sediment at the bottom of the tube. Finally, wash the cells 3 times with pre-cooled PBS, centrifuge again at low temperature, discard the supernatant to recover the cells, and add an appropriate amount of protein extraction solution according to the amount of cells to extract the protein.
[0080] The parietal peritoneum was paraffin-embedded and sectioned, and the tissue was fixed in OCT for frozen section preparation.
[0081] Animal experiment sample test results
[0082] Compared with the control group, the ultrafiltration volume of the model group was reduced, while the betaine treatment group was able to improve peritoneal function and significantly increase ultrafiltration volume; this indicates that after adding the osmotic regulating substance betaine to the peritoneal dialysis fluid, the ultrafiltration function of the peritoneum was significantly increased, enhancing the ultrafiltration effect of peritoneal dialysis. The LDH content in the dialysate of the model group was significantly higher than that of the normal control group, while the LDH content in the dialysate of the betaine treatment group was not much different from that of the normal control group, indicating that the betaine treatment group can effectively reduce the release of LDH. The model group suggests that cell pyroptosis is involved in the process of peritoneal function changes, while betaine can effectively resist peritoneal function changes ( Fig.14 ). Masson staining of tissues showed that in the normal control group, the peritoneal tissue was thin and continuous, while in the model group, obvious collagen deposition was observed under the mesothelium and the peritoneum was thickened compared with the normal group. The peritoneum in the betaine treatment group was slightly thicker than that in the normal group, but thinner than that in the model group ( Fig.15 ).
[0083] Example 4 shows that directly adding an appropriate amount of betaine to the existing commercial peritoneal dialysis fluid can protect peritoneal cells, improve peritoneal function, and improve the peritoneal dialysis effect. Example 3 shows that the combined use of sodium pyruvate and betaine can further reduce cell death such as pyroptosis and apoptosis of peritoneal mesothelial cells. Therefore, adding an appropriate amount of betaine and sodium pyruvate to the existing peritoneal dialysis fluid at the same time will further improve its cell protection effect, further improve the peritoneal dialysis effect, reduce peritoneal fibrosis, and significantly delay the occurrence of peritoneal dialysis ultrafiltration failure.
[0084] The above detailed description of the present invention is intended to enable persons familiar with the art to understand the contents of the present invention and implement them. It does not limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.
Claims
1. A peritoneal dialysis composition, comprising a peritoneal dialysis fluid, characterized in that: The peritoneal dialysis composition further comprises sodium pyruvate and betaine, wherein the concentration of the sodium pyruvate in the peritoneal dialysis composition is 1 to 300 mg / L, the concentration of the betaine in the peritoneal dialysis composition is 0.01 to 1000 mmol / L, and the peritoneal dialysis fluid is 1.5% to 2.5% glucose peritoneal dialysis fluid, 1.5% to 2.5% amino acid peritoneal dialysis fluid, 1.5% to 2.5% dextran peritoneal dialysis fluid or 6% to 8% icodextrin peritoneal dialysis fluid.
2. The peritoneal dialysis composition according to claim 1, characterized in that: The concentration of the sodium pyruvate in the peritoneal dialysis composition is 50-150 mg / L.
3. The peritoneal dialysis composition according to claim 1, characterized in that: The concentration of the betaine in the peritoneal dialysis composition is 1-500 mmol / L.
4. The peritoneal dialysis composition according to claim 1, characterized in that: The concentration of betaine in the peritoneal dialysis composition is 1-50 mmol / L.
5. The peritoneal dialysis composition according to any one of claims 1 to 4, characterized in that: Each 100 mL of the peritoneal dialysis solution contains the following components: The pH value of the peritoneal dialysis fluid is 5.0-6.
0. The peritoneal dialysis fluid matrix is one or more of glucose, amino acid or dextran.
6. The peritoneal dialysis composition according to claim 5, characterized in that: Each 100 mL of the peritoneal dialysis solution contains the following components: The pH value of the peritoneal dialysis fluid is 4.5-6.
0.
7. The peritoneal dialysis composition according to claim 5, characterized in that: Each 100 mL of the peritoneal dialysis solution contains the following components: The pH value of the peritoneal dialysis fluid is 4.5-6.
5.
8. The peritoneal dialysis composition according to any one of claims 1 to 4, characterized in that: Each 100 mL of the peritoneal dialysis solution contains the following components: The pH value of the peritoneal dialysis fluid is 5.0-6.
0.
9. The peritoneal dialysis composition according to claim 8, characterized in that: Each 100 mL of the peritoneal dialysis solution contains the following components: The pH value of the peritoneal dialysis fluid is 5.0-6.
0.
10. The peritoneal dialysis composition according to claim 1, characterized in that The preparation method of the peritoneal dialysis composition is: mixing the sodium pyruvate and betaine with the peritoneal dialysis fluid to obtain the peritoneal dialysis composition, or mixing the sodium pyruvate and betaine with the raw materials of the peritoneal dialysis fluid to obtain the peritoneal dialysis composition.
